Somewhat Favorable Media Coverage Somewhat Unlikely to Impact CTI BioPharma Corp. (CTIC) Stock Price
Media headlines about CTI BioPharma Corp. (NASDAQ:CTIC) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CTI BioPharma Corp. earned a news impact score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.194725148057 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Separately, Jefferies Group LLC initiated coverage on CTI BioPharma Corp. in a research note on Tuesday, September 12th. They set a “buy” rating and a $7.50 price objective for the company.
CTI BioPharma Corp. (NASDAQ:CTIC) traded up 1.23% during midday trading on Tuesday, reaching $3.29. The company’s stock had a trading volume of 6,552 shares. CTI BioPharma Corp. has a 52 week low of $0.36 and a 52 week high of $6.48. The company’s 50-day moving average is $3.33 and its 200 day moving average is $3.74. The firm’s market capitalization is $104.38 million.
CTI BioPharma Corp. (NASDAQ:CTIC) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%. The company had revenue of $22.23 million during the quarter. Analysts expect that CTI BioPharma Corp. will post ($1.26) earnings per share for the current fiscal year.
About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.